Bronchial epithelial cells represent the first line of defense against microorganisms and allergens in the airways and play an important role in chronic inflammatory processes such as asthma. In an experimental model, both RvD1 and AT-RvD1, lipid mediators of inflammation resolution, ameliorated some of the most important phenotypes of experimental asthma. Here, we extend these results and demonstrate the effect of AT-RvD1 on bronchial epithelial cells (BEAS-2B) stimulated with IL-4. AT-RvD1 (100 nM) decreased both CCL2 and CXCL-8 production, in part by decreasing STAT6 and NF-κB pathways. Furthermore, the effects of AT-RvD1 were ALX/FRP2 receptor dependent, as the antagonist of this receptor (BOC1) reversed the inhibition of these chemokines by AT-RvD1. In addition, AT-RvD1 decreased SOCS1 and increased SOCS3 expression, which play important roles in Th1 and Th17 modulation, respectively. In conclusion, AT-RvD1 demonstrated significant effects on the IL-4-induced activation of bronchial epithelial cells and consequently the potential to modulate neutrophilic and eosinophilic airway inflammation in asthma. Taken together, these findings identify AT-RvD1 as a potential proresolving therapeutic agent for allergic responses in the airways.

1. Introduction

Asthma is an inflammatory disease of the airways characterized by the migration and accumulation of leukocytes, particularly eosinophils, mucus hypersecretion, and bronchial hyperreactivity. The pathophysiology of asthma is coordinated by the immune response of CD4+ T cells, specifically the Th2 phenotype. IL-4 is the major cytokine involved in the Th2 immune response. IL-4 uses Janus kinases (JAKs) to initiate the signaling cascade and activate signal transducer and activator of transcription 6 (STAT6), consequently modulating allergic airway inflammation in asthma and other diseases [1]. Most patients with asthma have symptoms that are readily controllable by standard asthma therapies, including β2-adrenergic agonists, low doses of inhaled corticosteroids, or leukotriene modifiers [2]. However, 5–10% of asthmatic individuals have poorly controlled disease with frequent exacerbations or symptoms that are
refractory to current therapy [3]. Th1 and Th7 cells promote neutrophil recruitment and have been associated with both severe and steroid-resistant asthma [4].

Bronchial epithelial cells are involved in the homeostasis and coordination of immune responses in the airways and represent the first line of defense against microorganisms and allergens in the lungs [5, 6]. These cells express pattern recognition receptors, such as Toll-like receptors (TLR), and protease-activated receptors (PARs), which recognize microorganisms and allergens, respectively [7, 8]. The activation of these receptors on epithelial cells induces the production of chemokines and the expression of adhesion molecules and cytokines [9, 10] that can influence dendritic cell maturation, T cell differentiation, and airway inflammation modulation [II–14]. Bronchial epithelial cells also express the receptor for IL-4 (IL-4RA), and the activation of these cells by IL-4 induces, among other inflammatory parameters [15], the production of chemokines, for example, CCL2, CXCL-8, among others [7, 13, 14, 16, 17], which modulate leukocyte traffic and consequently airway inflammation in asthma.

During inflammation, the essential omega-3 fatty acid docosahexaenoic acid (DHA; C22:6) is available for enzymatic transformation into several anti-inflammatory and pro-resolving mediators, including the class of molecules termed resolvins [18]. Resolvin and its epimer, aspirin-triggered-resolvin D1 (AT-RvD1, R configuration at carbon 17), are enzymatically derived from DHA and demonstrate anti-inflammatory and pro-resolving effects in several experimental models, including in the airways in acute lung injury [19] and experimental airway allergic inflammation induced by ovalbumin [20] in mice. In this study, we investigated the role of AT-RvD1 on bronchial epithelial cells stimulated with IL-4.

2. Materials and Methods

2.1. Bronchial Epithelial Cells. The human bronchial epithelial cell line BEAS-2B (ATCC, Rockville, MD) was cultured in Dulbecco’s modified Eagle’s medium (DMEM-F12/Gibco-Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco-Life Technologies) and 1% penicillin + streptomycin (Gibco-Life Technologies, Carlsbad, CA, USA) and incubated at 37°C in a humidified atmosphere with 5% CO2 and 95% ambient air.

2.2. Stimulus and Treatment. AT-RvD1 was donated by Dr. David Bruce Levy of the Harvard Medical School. BEAS-2B (4 x 10^5 cell/mL) cells were cultivated in 96-well plates and treated with AT-RvD1 (1-100 nM) or vehicle (absolute alcohol) for 30 minutes prior to IL-4 (25 ng/mL) [17] stimulation. The use of BOC1 (10 μM), an ALX receptor antagonist, followed the same experimental procedure described above but was added 15 min before treatment with AT-RvD1 [21].

2.3. CCL2 and CXCL-8 Production in the Supernatant of Cells Treated with AT-RvD1 to Chemokine Quantification. The supernatant was collected at 24 h after IL-4 stimulation, and the CCL2 and CXCL-8 concentrations were measured by enzyme-linked immunosorbent assays (ELISA) according to the manufacturers’ instructions (BD Pharmingen, San Diego, CA, USA).

2.4. Expression of NF-κB and STAT6 in Cells Treated with AT-RvD1. The effect of AT-RvD1 on the NF-κB and STAT6 pathways was assessed by cytometry according to Cao et al. [22]. Briefly, 15 min after IL-4 stimulation, cells were fixed with pre-warmed BD Cytofix Buffer (4% paraformaldehyde) for 10 min at 37°C. After centrifugation, the cells were permeabilized in ice-cold methanol for 30 min and then stained with mouse monoclonal antibodies against anti-NF-κB (BD Biosciences Pharmingen, Phosflow, USA), anti-STAT6 (BD Biosciences Pharmingen, Phosflow, USA), or their corresponding mouse IgG2b isotype (BD Biosciences Pharmingen, Phosflow, USA) for 60 min followed by an FITC- or PE-conjugated goat anti-mouse IgG2b secondary antibody for another 45 min at 10°C in the dark. The cells were then washed, resuspended, and subjected to analysis. The expression of intracellular phosphorylated signaling molecules in 50,000 viable cells was analyzed by flow cytometry (FACSCalibur; BD Biosciences Pharmingen).

The results for phosphorylated NF-κB and STAT6 are shown as a percentage of fluorescence and are expressed as the arithmetic mean.

2.5. SOCS1 and SOCS3 Expression. At 1 h after IL-4 stimulation, total RNA was extracted from cells using Pure Linkr RNA Mini Kit (Life Technologies, Carlsbad, CA, USA). cDNA was synthesized by reverse transcription (RT) from total RNA with SuperScript VILO MasterMix (Invitrogen), Carlsbad, CA, USA) according to the manufacturer’s instructions. Duplicate qPCR reactions were performed with primers for SOCS1 (Forward: 5’T-TTTTTCGGCCCTTAGC-GTGA-3’, Reverse: 5’T-AGCACGCTGAAGAGGCCAGTC-3’) and SOCS3 (Forward: 5’T-GAGGCGCAGCTACAGTCT-3’, Reverse: 5’T-TCCCTATGTGCACCGAGATT-3’) and control GAPDH (Forward: 5’T-CCACCATGGAATCC-3’, Reverse: 5’T-TGAGCGCCTGGAATGTGGT-3’) (Life Technologies) using cDNA-specific TaqMan Gene Expression Assays with an ABI 7500 Fast Real-Time PCR System (Applied Biosystems). In each 5 μL TaqMan reaction, cDNA (corresponding to 100 ng reverse transcribed RNA) was mixed with 0.25 μL TaqMan Gene Expression Assay, 2.5 μL TaqMan Universal PCR Master Mix (Applied Biosystems), and 1.25 μL H2O. The PCR conditions were 95°C for 20 s, followed by 50 cycles at 95°C for 3 s, and 60°C for 30 s. Negative control reactions with no cDNA present and three interrun calibration samples were included on each assay plate.

The Ct (cycle threshold) values for SOCS1 and SOCS3 mRNA were normalized to GAPDH to provide the delta Ct values. The relative mRNA expression was determined using the Livak method (the 2^−ΔΔCt method for real-time PCR) [23].

2.6. Statistical Analysis. The results were expressed as the mean ± standard error of the mean. An evaluation of the results was performed by an analysis of variance (ANOVA) followed by a Tukey post-test among the means using GraphPad PRISM (Version 6.0; GraphPad Software Inc., San
Figure 1: AT-RvD1 reduced the production of CCL2 (a) and CXCL-8 (b) in bronchial epithelial cells stimulated with IL-4. BEAS-2B cells were stimulated with IL-4 (25 ng/mL) in the presence or absence of AT-RvD1 (1–100 nM) for 24 h, and the culture supernatants were analyzed to determine CCL2 and CXCL-8 concentrations using an ELISA kit. The data are reported as the means ± SEM (n = 7). ∗P < 0.05 versus control group; ∗P < 0.05 versus IL-4-treated group.

3. Results

3.1. AT-RvD1 Reduces the Concentration of Chemokines. The activation of bronchial epithelial cells induces, among others, the release of chemokines [7, 13, 14, 16, 17]. Therefore, we evaluated the role of AT-RvD1 in CCL2 and CXCL-8 production in bronchial epithelial cells stimulated with IL-4. Our results showed that IL-4 stimulation (25 ng/mL for 24 h) induced a prominent increase in CCL2 and CXCL-8 concentrations compared to nonstimulated cells (control group; Figures 1(a) and 1(b), resp.). At all doses (1–100 nM), AT-RvD1 significantly reduced CCL-2 (Figure 1(a)) and CXCL-8 (Figure 1(b)) production when compared with the cells treated with IL-4, whereas no significant difference was observed in cells treated with vehicle compared to cells treated with IL-4 (data not shown).

3.2. The Inhibitory Effect of AT-RvD1 on Chemokine Production Is ALX/FPR2 Receptor Dependent. The results presented above demonstrated that AT-RvD1 modulated the chemokine production induced by IL-4 in bronchial epithelial cells. Recent findings have shown that AT-RvD1 exerts part of its proresolving effects via interactions with the ALX/FPR2 receptor present on bronchial epithelial cells [24, 25]. Accordingly, we verified whether the ALX/FPR2-selective antagonist, BOC1, is capable of blocking the effects of AT-RvD1 on chemokine release by BEAS-2B cells after IL-4 stimulation.

As demonstrated above, IL-4 stimulated CCL-2 and CXCL-8 production, and AT-RvD1 reduced both (Figures 2(a) and 2(b), resp.). Interestingly, BOC1 significantly reversed the inhibitory effect of AT-RvD1 on CCL2 (Figure 2(a)) and CXCL-8 (Figure 2(b)) production. No significant difference was observed in cells stimulated with IL-4 and treated with BOC1 (10 μM) when compared with cells treated with IL-4.

3.3. AT-RvD1 Downregulates the Phosphorylation of Transcription Factors. We next evaluated the effect of AT-RvD1 on the STAT6 and NF-κB pathways. Signal transducer and activator of transcription 6 (STAT6) and nuclear factor kappa B (NF-κB) have been demonstrated to regulate many pathologic features of asthma, and both are activated by IL-4 [26, 27]. As shown in Figures 3(a) and 3(b), IL-4 induced the significant phosphorylation of NF-κB and STAT6 in cells compared to the control. Of note, AT-RvD1 significantly reduced cells expressing of NF-κB (Figure 3(a)) and STAT6 (Figure 3(b)) when compared to cells treated only with IL-4.

3.4. AT-RvD1 Acts in Modulating the Expression of SOCS1 and SOCS3. As the SOCS family is known to inhibit STAT signaling, we next evaluated the effect of AT-RvD1 on SOCS1 and SOCS3. In these experiments, the dose of 50 ng/mL was used for stimulation because the dose of 25 ng/mL did not induce the SOCSs expression (data not shown); this is in agreement with previous results [27]. The results showed that AT-RvD1 significantly reduced the expression of SOCS1 when compared with cells stimulated with IL-4 (Figure 4(a)); moreover, AT-RvD1 significantly increased SOCS3 expression (Figure 4(b)).
Figure 2: AT-RvD1 reduces CCL2 (a) and CXCL-8 (b) production in BEAS-2B cells stimulated with IL-4 through ALX/FPR2 receptor activation. BEAS-2B cells were stimulated with IL-4 (25 ng/mL) in the presence or absence of AT-RvD1 (100 nM) or in combination with BOC1, an ALX selective antagonist (10 μM), for 24 h; the culture supernatants were analyzed for CCL2 and CXCL-8 concentrations using an ELISA kit. The data are reported as the means ± SEM (n = 7). *P < 0.05 versus control group, #P < 0.05 versus IL-4-treated group, and +P < 0.05 versus IL-4 + AT-RvD1 (100 nM) treated group.

Figure 3: AT-RvD1 downregulates the NF-κB (a) and STAT6 (b) pathways in bronchial epithelial cells stimulated with IL-4. BEAS-2B cells were stimulated with IL-4 (25 ng/mL) for 15 min in the presence or absence of AT-RvD1 (100 nM). The results are expressed as the arithmetic mean plus SEM from three independent experiments (n = 4). *P < 0.05 versus control group; #P < 0.05 versus IL-4-treated group.
4. Discussion

IL-4 coordinates the Th2 immune response, which is associated with the pathophysiology of asthma. Interesting lipid mediators of resolution, such as AT-RvD1, demonstrate significant anti-inflammatory and proresolution effects in several experimental models. Here, we demonstrate for the first time the effect of AT-RvD1 in bronchial epithelial cells stimulated with IL-4. AT-RvD1 significantly reduced CCL2 and CXCL-8 production when compared to cells treated with IL-4. These effects are ALX/FPR2 receptor dependent and in part associated with the downregulation of STAT6 and NF-κB pathways by AT-RvD1. Therefore, AT-RvD1 decreased SOCS1 and increased SOCS3 expression, which play critical roles in lymphocyte differentiation, maturation, and function. These results suggest that AT-RvD1 can modulate the innate and adaptive immune responses of asthma and other diseases, but further studies are needed for confirmation.

IL-4 is the major factor in the differentiation of the Th2-type immune response and blocks the differentiation of Th1 cells by indirect inhibiting interferon-γ (IFN-γ) [28]. Bronchial epithelial cells express IL-4 receptor (IL-4R), and IL-4 induces the production of chemokines such as CCL2 and CXCL-8, among other inflammatory parameters [7, 22, 24–26]. CCL2, also known as monocyte chemotactic protein-1 (MCP-1), is a potent chemotactic for monocytes and is produced constitutively or after stimulation in various cell types, including bronchial epithelial cells [27]. Indeed, CCL2 is chemotactic to monocytes/macrophages, basophils, eosinophils, and Th2 cells. In addition, CCL2 is involved in the polarization of Th2 cells and therefore is associated with the pathogenesis of allergic inflammatory diseases, such as asthma [29, 30]. Most patients with asthma have symptoms that are readily controllable by standard asthma therapies [2]. However, 5–10% of asthmatic individuals have poorly controlled disease with frequent exacerbations or symptoms that are refractory to current therapy [2, 3]. Distinct from the airway inflammation of stable asthma, which has been attributed to ongoing Th2-mediated inflammation, with a predominance of eosinophils and lymphocytes, there is increasing evidence to suggest that the increased inflammation in asthma exacerbation is under different regulation [31]. In addition to the eosinophils and lymphocytes that predominate in Th2-type inflammation, asthma exacerbations are notable for a neutrophil-enriched inflammatory response, which in some cases is the principal cellular infiltrate. Neutrophils are the major inflammatory cell in the airways of individuals dying within several hours of an asthma attack and are found in increasing numbers in patients dying of status asthmatics [32]. Their numbers are increased in the sputum and bronchial washings of patients intubated for status asthmaticus [33–35]. There are several chemoattractants for neutrophils, such as the CXCL-8 [36] and the lipid mediator leukotriene B4 (LTB4) [37]. CXCL-8 is a chemokine that is mainly involved in the recruitment of neutrophils and exerts this effect by binding to two cell surface receptors, chemokine receptors CXCR1 and CXCR2 [36]. In addition to neutrophils, CXCL-8 may also recruit B and T lymphocytes, NK cells, and dendritic cells [38–40]. In addition, CXCL-8 induces the degranulation of neutrophils, basophils, and macrophages [41].

LTB4 and proinflammatory lipid mediators are well known to play important roles in asthma [42], but not all lipid mediators are associated with inflammation. For example, lipoxins and resolvins and their epimers are lipid mediators generated during the resolution phase and demonstrate significant anti-inflammatory and proresolution effects [43, 44]. In a previous study, our group demonstrated that AT-RvD1 markedly decreased airway eosinophilia and mucus
metaplasia, in part by decreasing IL-5 and IkBa degradation in allergen-sensitized and challenged mice. In addition, AT-RvD1 significantly enhanced the macrophage phagocytosis of IgG-OVA-coated beads in vitro and in vivo, a new proresolving mechanism for the clearance of allergens from the airways [20]. In the present work, AT-RvD1 significantly reduced CCL2 and CXCL-8 production in bronchial epithelial cells when compared to cells stimulated with IL-4, demonstrating the potential to reduce both neutrophilic and eosinophilic inflammation in asthma.

AT-RvD1 can serve as an agonist for the ALX/FPR2 receptor to transduce, in part, its proresolution action [45–48]. The ALX/FPR2 receptor is broadly expressed in airway epithelial cells and alveolar macrophages and is dynamically regulated during allergic airway responses, leading to decreased receptor abundance [20, 49]. These changes are similar to those observed in human asthma [50]. We demonstrated that the inhibitory effect of AT-RvD1 on chemokine production by BEAS-2B cells stimulated with IL-4 is ALX/FPR2 receptor dependent, because the antagonist of this receptor reversed its effects.

Several transcription factors have also been implicated in the inflammatory process of asthma, including STAT6 and NF-κB [51–54]. STAT6 has been demonstrated to regulate many pathologic features of lung inflammatory responses, including Th2 cell differentiation, airway eosinophilia, epithelial mucus production, and smooth muscle changes [55, 56]. NF-κB controls the expression of some relevant genes encoding chemokines (CCL11, CXCL-8), cytokines (IL-5), and adhesion molecules (P-selectin) involved in airway eosinophilic and/or neutrophilic inflammation [57–60]. AT-RvD1 demonstrated a significant effect in reducing the phosphorylation of both STAT6 and NF-κB in BEAS-2B cells stimulated with IL-4. The downregulation of NF-κB by AT-RvD1 is in agreement with a previous study by our group [19, 20]; however, the present study is the first to demonstrate STAT6 modulation by AT-RvD1.

The JAK/STAT pathways have a pivotal role in the differentiation of helper T cells. The SOCS family, induced by cytokine stimulation, inhibits STAT signaling [59, 60]. SOCS1 has been shown to be a critical negative regulator of IFN-γ and consequently of the Th1 immune response [61]. SOCS3 promotes Th2 differentiation by blocking STAT4 signaling. However, the removal of SOCS3 from T cells inhibits Th1 and Th2 responses [62, 63]. In addition, SOCS3 blocks STAT3 signaling and consequently inhibits Th17 polarization [64]. IL-17 plays an important role in the development of severe asthma due to induced neutrophilic inflammation [65, 66]. Therefore, the inhibition of Th17 cell differentiation or IL-17 production could be beneficial for controlling severe asthma. SOCS plays an important role in the modulation of inflammation and is critical due to its broad spectrum of signaling events. However, the role of SOCS in bronchial epithelial cells is not clear. In our experiments, IL-4 increased both SOCS1 and SOCS3 expression, with SOCS1 showing higher expression, whereas AT-RvD1 decreased SOCS1 and increased SOCS3 expression compared to cells stimulated with IL-4. Thus, it is possible that SOCS1 inhibition and SOCS3 induction, involved in Th1 and Th17 immune responses, respectively, by AT-RvD1 may also negatively regulate JAK/STAT signaling pathways in BEAS-2B cells. However, additional studies are needed to test this hypothesis. Taken together, the results suggested that AT-RvD1 has a potential to modulate the immune response in both stable and severe asthma.

5. Conclusion

In conclusion, our results demonstrate that AT-RvD1 modulates the activation of bronchial epithelial cells induced by IL-4. AT-RvD1, via the ALX/FPR2 receptor, decreased CCL2 and CXCL-8 production and downregulated the NF-κB and STAT6 pathways. In addition, AT-RvD1 decreased SOCS1 and increased SOCS3 expression. Together, these results suggest that AT-RvD1 has the potential to control airway inflammation.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (no. 475349/2010-5), Fundação de Apoio a Pesquisa do Estado de Minas Gerais (FAPEMIG) (no. 01/11 CDS APQ 01631/11), Rede de Pesquisa em Doenças Infecciosas Humanas e Animais do Estado de Minas Gerais (code REDE 20/12), and Universidade Federal do Triângulo Mineiro (UFTM), Brazil.

References


